Trial Profile
Tianjin Medical University Cancer Institute and Hospital
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Paclitaxel
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 27 Nov 2017 Status changed from active, no longer recruiting to recruiting.
- 22 Nov 2017 New trial record